{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:42:07Z","timestamp":1790743327299,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,4,7]],"date-time":"2016-04-07T00:00:00Z","timestamp":1459987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>The present study evaluated the pharmacodynamics and pharmacokinetics of nebivolol enantiomers in patients with chronic kidney disease (CKD) and in patients undergoing haemodialysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Forty\u2010three adult patients were distributed into three groups: healthy volunteers and hypertensive patients with normal kidney function (<jats:italic>n<\/jats:italic> = 22); patients with stage 3 and 4 CKD (<jats:italic>n<\/jats:italic> = 11); and patients with stage 5 CKD undergoing haemodialysis (<jats:italic>n<\/jats:italic> = 10). The subjects received a single oral dose of 10\u00a0mg racemic nebivolol. Serial blood samples were collected up to 48\u00a0h after administration of the drug and heart rate variation was measured over the same interval during the isometric handgrip test. The nebivolol enantiomers in plasma were analysed by liquid chromatography\u2013tandem mass spectrometry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The pharmacokinetics of nebivolol is enantioselective, with a greater plasma proportion of <jats:italic>l<\/jats:italic>\u2010nebivolol. CKD increased the area under the concentration\u2013time curve (AUC) of <jats:italic>l<\/jats:italic>\u2010nebivolol (6.83\u00a0ng.h ml<jats:sup>\u20131<\/jats:sup> <jats:italic>vs<\/jats:italic>. 9.94\u00a0ng.h ml<jats:sup>\u20131<\/jats:sup>) and <jats:italic>d<\/jats:italic>\u2010nebivolol (4.15\u00a0ng.h ml<jats:sup>\u20131<\/jats:sup> <jats:italic>vs<\/jats:italic>. 7.30\u00a0ng.h ml<jats:sup>\u20131<\/jats:sup>) when compared with the control group. However, the AUC values of <jats:italic>l<\/jats:italic>\u2010nebivolol (6.41\u00a0ng.h ml<jats:sup>\u20131<\/jats:sup>) and <jats:italic>d<\/jats:italic>\u2010nebivolol (4.95\u00a0ng.h ml<jats:sup>\u20131<\/jats:sup>) did not differ between the haemodialysis and control groups. The administration of a single dose of 10\u00a0mg nebivolol did not alter the heart rate variation induced by isometric exercise in the investigated patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Stage 3 and 4 CKD increases the plasma concentrations of both nebivolol enantiomers, while haemodialysis restores the pharmacokinetic parameters to values similar to those observed in the control group. No significant difference in heart rate variation induced by isometric exercise was observed between the investigated groups after the administration of a single oral dose of 10\u00a0mg nebivolol.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.12917","type":"journal-article","created":{"date-parts":[[2016,2,25]],"date-time":"2016-02-25T16:58:51Z","timestamp":1456419531000},"page":"83-91","source":"Crossref","is-referenced-by-count":16,"title":["Influence of chronic kidney disease and haemodialysis treatment on pharmacokinetics of nebivolol enantiomers"],"prefix":"10.1111","volume":"82","author":[{"given":"Daniel V.","family":"Neves","sequence":"first","affiliation":[{"name":"Department of Clinical Analysis, Food Science and Toxicology, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto SP Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera L.","family":"Lanchote","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis, Food Science and Toxicology, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto SP Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Moys\u00e9s Neto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto SP Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Cardeal da Costa","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto SP Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina P.","family":"Vieira","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis, Food Science and Toxicology, School of Pharmaceutical Sciences of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto SP Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo B.","family":"Coelho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine of Ribeir\u00e3o Preto University of S\u00e3o Paulo  Ribeir\u00e3o Preto SP Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,4,7]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.931371"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.59"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.163"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9626-3"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007090974"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2010.05.009"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.018192"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011413588"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000245631"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3280f9df85"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.164780"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2007.07.003"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(91)90502-V"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03258259"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.07.004"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-006-0250-8"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2011.09.037"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0678-8"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-012-0258-1"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/S0272-6386(04)00369-5"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(97)00074-3"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1997.54212.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(01)01577-7"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2013.09.031"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199206000-00002"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03029745"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010370846"},{"key":"e_1_2_9_29_1","doi-asserted-by":"crossref","first-page":"P38","DOI":"10.1016\/j.clpt.2004.12.037","article-title":"Effects of varying degrees of renal impairment on the pharmacokinetic disposition of nebivolol","volume":"77","author":"Shaw A","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2013.399"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706138"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199906000-00002"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0b013e3283136732"},{"key":"e_1_2_9_34_1","first-page":"71","article-title":"Formulation, optimization and evaluation of oral nanosuspension tablets of nebivolol hydrochloride for enhancement of dissolution rate","volume":"7","author":"Thadkala K","year":"2015","journal-title":"Der Pharm Lett"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2006060610"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007760515117"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.2001.281.4.R1134"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02796.x"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.115.05858"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198805000-00007"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-200112003-00003"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12917","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.12917","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.12917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T22:38:45Z","timestamp":1696372725000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.12917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["10.1111\/bcp.12917"],"URL":"https:\/\/doi.org\/10.1111\/bcp.12917","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,7]]}}}